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INTRODUCTION 
Acute pulmonary thromboembolism afflict lakhs of people throught the 
world and is the third most common problem after coronary artery disease and 
cerebrovascular accident. The case fatality rate is 15 percent and it exceeds 
the mortality rate of acute myocardial infarction 
The high mortality rate of pulmonary embolism is failure to diagnose 
or suspecting in an appropriate patient 
In autopsy studies when the pathologist judged PE contributed to the 
death, the diagnosis was unsuspected ante-mortem in over one- half cases 
Awareness of PE for clinicians is important at all levels of care so that 
early diagnosis and proper timely referral are made  
In 1856 Rudolf Virchow postulated that a triad of factors predisposed 
to thrombosis 
1) Local trauma to the vessel 
2) Hypercoagulability 
3) Stasis 
One of the above factors or combination of the factors lead to PE 
 In the era of lot of air travel, people are more prone for PE1,2 
Nowadays lot of old age people are undergoing surgery and they are 
kept immobile making them prone for PE. 
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Obesity has become common as people are using vehicles for even 
short distance.For each 40% increase in weight there is two fold increase in 
incidence of PE.3 
Incidence of PE increases exponentially with age and is more frequent 
in adults than in children.4 
Incidence of PE is more common in smokers. 
Malignancy incidence is increasing and treatment with chemotherapy 
heightens the risk of DVT and PE.5 
Stroke and congestive heart failure are predisposing factors. 
Inherited  hypercoagulable factors remains silent until an  acquired 
stress occurs. 
Immobilization irrespective of the cause is the most frequent 
predisposing factor. 
Deep Venuos Thrombosis is the origin of PE in 80% of cases.A 
difference of circumference of the calves of 1 cm or more, measured 10 cm 
below the tibial tuberosity is abnormal. Valve pockets are frequent site of 
origin of thrombi.These venous thrombi detach from their sites of formation 
they flow toward the vena cava,they go to right atrium, right ventricle and 
enter pulmonary artery.DVT is detected only in 30% of the cases after they 
embolize to pulmonary circulation. 
The extent of pulmonary obstruction will determine the severity, 
clinical features and the prognosis.  
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Small to moderate PE patients are clinically stable. 
Moderate to large (sub massive) PE patients have one third or more of 
the vasculature obstruction. 
 Massive pulmonary embolism patients have thrombosis affecting  
atleast half of pulmonary arterial vasculature. 
As obstruction increases pulmonary hypertension is caused by 
chemicals such as serotonin, reflex vasoconstriction and hypoxia. 
The overloaded right ventricle release biomarkers such as brain 
natriuretic pepetide and troponin.6 
As the right ventricle dilates the intervenricular septum shifts to left 
leading to hypotension. 
Increased wall tension of RV reduces right coronary flow and causes 
ischemia.7 
PE at the bifurcation leads to collapse of the patient. More commonly 
embolus lodges at one of the branches of pulmonary artery. 
In a French study when PE was diagnosed appropriate citeria was used 
in 92% of patients but when PE excluded inappropriate criteria were used in 
57% of the cases.8 
Two factors predisposed to error 
1 Lack of algorithm 
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2 Not doing additional tests in elevated D-dimer cases 
Another problem is delayed presentation.9 
PE is a great masquerader of diseases. 
Symptoms like dyspnoea are often thought of as symptom of other 
diseases. 
Signs are that of right ventricular hypertension that are obvious in 
some of the cases. 
Investigations like ecg echocardiogram ,D-dimer 10 Ventilation-
Perfusion scan CT scan are helpful. 
So the diagnosis of PE requires constellation of predisposing factors, 
symptoms, signs and investigations and high degree of suspiscion. 
PE when it is massive  or sometimes submassive is an emergency 
where we have to asses the probability of PE quickly to proceed further. 
PROBABILITY OF PE  
To assess the probability of PE in a patient there are two models 
WELLS(Canada) and revised GENEVA  that are currently followed . 
WELLS model takes in to account-mostly positive variables 
• DVT symptoms or signs, 
• No alternate diagnosis, 
• Heart rate, 
• History of immobilization or surgey within 4 weeks, 
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• Prior DVT or PE, 
• Haemoptysis, 
• Cancer treated within 6 month or metastatic 
REVISED GENEVA MODEL takes into account-positive variables 
• Age 
• Previous DVT  or PE 
• Surgery or fracture in 1 month 
• Active malignancy 
• Unilateral limb pain 
• Haemoptysis 
• Heart rate 
• Pain on lower limb deep vein palpation and  unilateral oedema 
In  PISA CITY of ITALY, Miniati et al introduced PISA MODEL for 
the prediction of PE11. 
 PISA MODEL contains 10 positive variables and 6 negative variables 
and takes into account ECG findings 
• 10 positive variables: 
o Older age 
o Male sex 
o Prolonged immobilisation  
o History of DVT 
o Sudden onset dyspnea  
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o Chest pain 
o Syncope 
o Hemoptysis 
o Unilateral leg swelling 
o Ecg signs of acute cor pulmonale  
• 6 negative variables: 
o Prior cardiovascular disease 
o Prior respiratory disease 
o Orthopnea 
o High fever 
o Wheeze 
o Crackles  
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PISA MODEL FORMATION-PROCESS 
This model was developed from Pisa city Italy by Miniati et al from 
the centre of excellence for pulmonary embolism11 
 Sample prevalence was done for all the variables collected in the 
1,100 patients, separately for patients with and those without pulmonary 
embolism. Age was the only  continuous variable, and it was grouped into 
four classes based on the quartiles of its  observed distribution (15–56, 57–67, 
68–74, and 75–94 yr). 
The univariate relationship between patients' baseline characteristics 
and the diagnosis of pulmonary embolism was assessed by Fisher's exact test 
or by Mann-Whitney nonparametric test. Two-tailed P values less than 0.05 
were considered statistically significant throughout.  
Logistic regression model for the probability of having pulmonary 
embolism was done.  
Initially, all the baseline variables were included in the model. Then, 
they were removed one by one, if not statistically significant. If the removal 
caused large changes (>10%) in the coefficients of any of the remaining 
variables, the removed variable was reintroduced into the model. In the 
model-building process, age and sex were considered known relevant 
predictors and were kept in the model regardless of their statistical 
significance. 
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In the final model, however, all the variables included were 
statistically significant. The area under the receiver operating characteristic 
(ROC) curve of the final model was reported, together with its 95% 
confidence interval (CI). All the analysis was performed on Stata (STATA 10; 
StataCorp, College Station, TX) and R software  
INTERNAL VALIDATION OF THE MODEL 
To estimate the predictive accuracy of model, when applied to a new 
set of patients, bootstrap resampling techniques was used. The area under the 
ROC curve from 1,000 bootstrap samples of size 1,100 that were randomly 
selected with replacement from the original 1,100-patient sample. 
EXTERNAL VALIDATION OF THE MODEL 
The predictive model, derived from the original 1,100-patient sample, 
was validated in an independent sample of 454 patients with suspected 
pulmonary embolism who were evaluated between January 1, 2003, and 
December 31, 2005. Fifty-four (12%) of them were excluded because of 
inability to obtain an informed consent (n = 28), or documented 
contraindications to pulmonary angiography (n = 26). The remaining 400 
patients were managed according to the diagnostic protocol described above. 
The clinical probability of pulmonary embolism was estimated at bedside by 
one of seven residents in respiratory medicine by using the proposed software 
on palm computers. Clinical probability was assessed before any further 
objective testing.  
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DERIVATION SAMPLE 
The 1,100 patients in the derivation sample had a median age of 68 
years (interquartile range [IQR], 57–75 yr); 45% of them were male, and 81% 
were hospitalized at the time of study entry. On the basis of angiography and 
autopsy findings, the prevalence of pulmonary embolism was calculated 
PREDICTIVE MODEL 
Sixteen variables were incorporated into a multivariate logistic 
regression model, of which 10 were positively and 6 were negatively 
associated with pulmonary embolism.  
Variables associated with an increased likelihood of pulmonary 
embolism were as follows: older age, male sex, prolonged immobilization, 
history of deep vein thrombosis, sudden-onset dyspnea, chest pain, fainting 
(or syncope), hemoptysis, and electrocardiographic signs of acute cor 
pulmonale. 
 Variables associated with a decreased likelihood of pulmonary 
embolism included prior cardiovascular or pulmonary disease, orthopnea, 
high fever, wheezes, or crackles on chest auscultation. The area under the 
ROC curve was 0.90 (95% CI, 0.88–0.91)12.  
The probability of pulmonary embolism can be calculated after adding 
all the applicable regression coefficients to the constant.  
Among the 440 patients with pulmonary embolism, there was a highly 
significant, positive relation between the clinical probability predicted by the 
model  
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INTERNAL VALIDATION 
The predictive model derived from the original 1,100-patient sample 
appeared to be accurate and parsimonious. The overall accuracy of the model, 
as measured by the ROC area, was validated based on 1,000 bootstrap 
samples. The area under the ROC curve on a sample of new independent 
patients was estimated to be 0.88.  
EXTERNAL VALIDATION 
The 400 patients in the validation sample had a median age of 70 years 
(IQR, 59–76 yr); 42% were male, and 71% were inpatients at the time of 
study entry.  
Pulmonary embolism was diagnosed by angiography in 165 (41%) of 
400 patients. The median extent of pulmonary vascular obstruction at baseline 
was 40% (IQR, 27–56%). Of the 235 patients without pulmonary embolism, 
83 had normal perfusion scans. None of them presented with symptomatic 
episodes of venous thromboembolism over a 6-month follow-up. 
The proportion of patients in each of probability categories and the 
relative prevalence of pulmonary embolism are reported in or the whole 
sample, and separately for inpatients and outpatients. In the validation 
sample, the area under the ROC curve was 0.88 (95% CI, 0.84–0.91), which 
was consistent with the estimate from the internal validation. 
 The prevalence of pulmonary embolism in outpatients (46%) was 
slightly but not significantly higher than in inpatients (39%, P value = 0.18 by 
Fisher's test). There was no significant difference between inpatients and 
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outpatients regarding the prevalence of pulmonary embolism in each of the 
probability categories. 
In the 165 patients with pulmonary embolism at inclusion, there was a 
highly significant, positive relation between the clinical probability predicted 
by the model and the severity of pulmonary embolism on the lung scan (P 
value < 0.001 by Kruskal-Wallis nonparametric test).  
 Pisa model is entirely based on the evaluation of relevant clinical 
symptoms and signs, and the interpretation of the electrocardiogram. 
Therefore, it is applicable in any clinical context 
In terms of predictive accuracy, model outperformed those reported by 
others The area under the ROC curve was 0.90 in the derivation sample, and 
0.88 in the validation sample.  
Among the patients with pulmonary embolism, there was a strong 
relation between the clinical probability predicted by the model   
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AIM OF THE STUDY 
 To compare Pisa Model with Wells Score and Revised Geneva Score in 
predicting the probability of pulmonary embolism  
 
 To validate Pisa Model in predicting the probability of pulmonary 
embolism in  Indian context 
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REVIEW OF LITERATURE 
Approximately 100,000 patients in the United States die each year 
directly as a consequence of acute pulmonary embolism (PE), with another 
100,000 deaths occurring in patients with concomitant disease in whom PE 
contributes significantly to their demise13,14. Three-month mortality in 
unselected patients with acute PE is as high as 15 percent15. 
Although a number of patients die of comorbidities that predisposed 
them to the thromboembolic event, a substantial number of patients die from 
PE within an hour of presentation, before the diagnosis can be confirmed and 
therapy initiated, or because the diagnosis was overlooked. 
Autopsy studies have repeatedly documented the high frequency with 
which PE has gone unsuspected and undetected. Despite advances in 
diagnostic imaging tests and therapeutic interventions, PE remains 
underdiagnosed and prophylaxis continues to be dramatically underused. 
Anticoagulation with heparin as a "bridge" to warfarin is still 
considered the standard treatment for PE. The spectrum of anticoagulant 
drugs has been expanded recently. Low-molecular-weight heparins (LMWHs) 
have been shown to be effective and safe for both treatment and for 
prevention of VTE, particularly in hospitalized medical patients. 
Fondaparinux, a new pentasaccharide, is very effective in a fixed low 
dose in preventing venous thromboembolism (VTE) after orthopedic and 
abdominal surgery, and has been demonstrated in clinical trials to be as 
  
14
effective as LMWH and unfractionated heparin for the initial treatment of 
patients with deep venous thrombosis and pulmonary embolism.  
RISK FACTORS AND PATHOGENESIS OF VENOUS 
THROMBOEMBOLISM 
In 1856, Virchow proposed his triad of factors leading to intravascular 
coagulation, including stasis, vessel wall injury, and hypercoagulability. Risk 
factors for deep venous thrombosis (DVT) are based on these processes  
The overwhelming majority of emboli originate from the deep veins of 
the lower extremities, although any venous bed can be involved. in wall, most 
originate in valve pockets.  
The veins of the calf are the most common site of origin, with 
subsequent extension of the clot prior to embolization. Eventually, the 
thrombus may expand to fill the vessel entirely, with both retrograde and 
proximal extension. If embolization does not occur, the thrombosis can 
partially or completely resolve via three mechanisms: recanalization, 
organization, and lysis.  
RISK FACTORS FOR VENOUS THROMBOEMBOLISM 
Acquired factors 
• Age older than 40  
• Prior history of venous thromboembolism  
• Prior major surgical procedure  
• Trauma  
• Hip fracture  
• Immobilization/paralysis  
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• Venous stasis  
• Varicose veins  
• Congestive heart failure  
• Myocardial infarction  
• Obesity  
• Pregnancy/postpartum period  
• Oral contraceptive therapy  
• Cerebrovascular accident  
• Malignancy  
• Severe thrombocythemia  
• Paroxysmal nocturnal hemoglobinuria 
• Antiphospholipid antibody syndrome (including lupus anticoagulant)  
Inherited factors  
• Antithrombin III deficiency  
• Factor V Leiden (activated protein C resistance)  
• Prothrombin gene (G20210A) defect  
• Protein C deficiency  
• Protein S deficiency 
• Dysfibrinogenemia  
• Disorders of plasminogen  
• Hyperhomocysteinemia  
Acquired Risk Factors 
Long automobile or airplane trips appear to be risk factors for VTE, 
and correlates with the flight distance. The risk of PE significantly increases 
with a flight distance >3107 miles (5000 km) or a duration >8 hours.  
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Obesity merits further investigation, because recent studies implicate 
obesity as a risk factor for VTE, body mass index 29 kg/m2 was an 
independent risk factor. The Framingham Study has confirmed that obesity is 
a risk factor for PE, particularly in women16. 
In addition to increased venous stasis, obesity may also increase the 
risk for VTE as a consequence of elevated plasma levels of certain clotting 
factor such as fibrinogen, factor VII, and plasminogen activator inhibitor-1, 
and as a result of platelet activation caused by enhanced lipid peroxidation. 
 An abundance of literature documents that the risk of venous 
thromboembolism increases with age, with a relative risk for those 70 years of 
age approximately 25-fold greater than the risk for those 20 to 29 years of 
age.. 
 Surgical patients with a previous history of VTE who do not receive 
prophylaxis develop postoperative DVT in more than 50 percent of cases. 
Surgery itself significantly enhances the risk. Patients who are undergoing 
general surgery without additional risk factors develop DVT in nearly 20 
percent of cases if neither pharmacologic nor mechanical prophylaxis is 
applied. Patients who are undergoing lower-extremity orthopedic procedures 
such as total hip or total knee replacement develop DVT in more than 50 
percent of cases. 
Trauma, particularly of the lower extremities and pelvis, heightens the 
risk of DVT. PE has been identified at autopsy in as many as 60 percent of 
patients with lower-extremity fractures, and mortality has been attributed to  
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PE in as many as 50 percent of patients dying after hip fracture. Upper-
extremity DVT has become more important because of an increasing use of 
pacemakers, implantable defibrillators, and long-term, indwelling, central 
venous catheters. Symptomatic PE can originate from upper-extremity 
thrombi, although this appears much less common than embolization from 
lower-extremity DVT.  
Upper-extremity DVT poses the risk of superior vena cava syndrome 
and loss of vascular access. Effort-related, upper-extremity axillosubclavian 
thrombosis (Paget-Schroetter syndrome)17 may occur spontaneously or be 
associated with an underlying thrombophilic tendency, and may result in 
significant, long-term functional impairment. 
Epidemiologic analyses, as well as autopsy data, suggest that patients 
with cardiac disease are predisposed to VTE Although myocardial infarction 
without anticoagulation is associated with a significant incidence of DVT, 
more recent therapeutic strategies for acute coronary syndromes have had a 
beneficial impact. Large, placebo-controlled acute myocardial infarction trials 
indicate that the use of thrombolytic therapy reduces the incidence of VTE.  
Cancer clearly augments the risk of VTE 
Following the administration of various chemotherapeutic agents, 
changes in the levels of coagulation factors, suppression of anticoagulant and 
fibrinolytic activity, and direct endothelial damage have been documented 
clinically and experimentally 
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Hormonal therapy, particularly tamoxifen in breast cancer adjuvant 
therapy, is also associated with an increased risk of thromboembolism, 
particularly when combined with chemotherapy. 
Neutropenia and sepsis, which often accompany chemotherapeutic 
regimens, often necessitate hospitalization and bedrest, which contributes 
further to the risk of VTE  
DVT appears to be more common in the third trimester and postpartum 
than prior to delivery, the risk is considerable throughout pregnancy.  
Cesarean section further augments the risk.  
Oral contraceptives are associated with an increased relative risk of 
venous thromboembolism, although the absolute risk (approximately 1 to 3 
cases per 10,000 woman-years) remains small. 
Oral contraceptive use should be avoided bywomen with protein C, 
protein S, and antithrombin III deficiency, as well as those who are 
homozygous carriers of the factor V Leiden mutation.  
PATHOPHYSIOLOGY OF ACUTE PULMONARY 
EMBOLISM 
GAS-EXCHANGE ABNORMALITIES 
Hypoxemia and hypocarbia are associated with acute embolism 
HEMODYNAMIC ALTERATIONS 
The hemodynamic effects of embolism are related to three factors: the 
degree of reduction of the cross-sectional area of the pulmonary vascular bed,  
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the preexisting status of the cardiopulmonary system, and the physiologic 
consequences of both hypoxic and neurohumorally mediated vasoconstriction. 
Obstruction of the pulmonary vascular bed by embolism acutely increases the 
workload on the right ventricle, a chamber ill-equipped to deal with high-
pressure load. In patients without preexisting cardiopulmonary disease, 
obstruction of less than 20 percent of the pulmonary vascular bed results in a 
number of compensatory events that minimize adverse hemodynamic 
consequences. Recruitment and distension of pulmonary vessels occur, 
resulting in a normal or near-normal pulmonary artery pressure and 
pulmonary vascular resistance; cardiac output is maintained by increases in 
the right ventricular stroke volume and increases in the heart rate. As the 
degree of pulmonary vascular obstruction exceeds 30 to 40 percent, increases 
in pulmonary artery pressure and modest increases in right atrial pressure 
occur. The Frank-Starling mechanism maintains right ventricular stroke work 
and cardiac output.  
When the degree of pulmonary artery obstruction exceeds 50 to 60 
percent, compensatory mechanisms are overcome, cardiac output begins to 
fall, and right atrial pressure increases dramatically. With acute obstruction 
beyond this amount, the right heart dilates, right ventricular wall tension 
increases, right ventricular ischemia may develop, the cardiac output falls, 
and systemic hypotension develops. In patients without prior cardiopulmonary 
disease, the maximal mean pulmonary artery pressure capable of being 
generated by the right ventricle appears to be 40 mmHg. The correlation 
between the extent of pulmonary vascular obstruction and the pulmonary 
vascular resistance appears to be hyperbolic, reflecting at its lower end the  
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expansible nature of the pulmonary vascular bed, and at its upper end, the 
precipitous decline in cardiac output that may occur as the right ventricle 
fails.18,19 The hemodynamic response to acute pulmonary embolism in 
patients with preexisting cardiopulmonary disease may be considerably 
different. Patients with prior cardiopulmonary disease demonstrate degrees of 
pulmonary hypertension that are disproportionate to the degree of pulmonary 
vascular obstruction. As a result, severe pulmonary hypertension may develop 
in response to a relatively small reduction in pulmonary artery cross-sectional 
area. Thus, evidence of right ventricular hypertrophy (rather than right 
ventricular dilatation) associated with a mean pulmonary artery pressure in 
excess of 40 mmHg should suggest an element of chronic pulmonary 
hypertension resulting from a potentially diverse group of etiologic 
possibilities (e.g., chronic thromboembolic pulmonary hypertension, left 
ventricular failure, valvular disease, right-to-left cardiac shunts). 
DIAGNOSIS OF DEEP VENOUS THROMBOSIS AND 
PULMONARY EMBOLISM 
History and Physical Examination 
The presence of erythema, warmth, pain, swelling, and/or tenderness 
are not specific for DVT but suggest the need for further evaluation. PE must 
always be considered when unexplained dyspnea is present. Pleuritic chest 
pain and hemoptysis are also common in PE. Coughing may be present, and 
while sometimes caused by PE, it more commonly occurs with bronchitis or 
pneumonia. Anxiety and light-headedness are symptoms that may be caused 
by PE but may also be caused by a number of other entities that result in 
hypoxemia or hypotension. Severe dyspnea and syncope are the principal  
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symptoms that may suggest massive, life-threatening PE. Tachypnea and 
tachycardia are the most common signs of PE, but they are also nonspecific. 
A pleural rub or accentuated pulmonic component of the second heart sound 
may suggest PE, but can also be explained by other disorders. With embolism 
of sufficient magnitude to cause right ventricular dysfunction, a murmur of 
tricuspid regurgitation, systemic hypotension, or jugular venous distension 
might be present. 
A major advance in the diagnostic approach to both venous 
thrombosis and pulmonary embolism has been a transition from a 
technique-oriented approach to one that utilizes Bayesian analysis. In 
doing so, the pretest probability of the disease, calculated independently 
of a particular test result through either empiric means or through a 
standardized prediction rule, is calculated. This pretest probability aids 
in the selection and interpretation of further diagnostic tests to create a 
posttest probability of the disease.  
This posttest probability can then be used as a basis for clinical 
decision making. For pulmonary embolism, three such scores have been 
developed and validated.  
Wells and coworkers prospectively tested a rapid seven-item bedside 
assessment to estimate the clinical pretest probability for PE.20 An alternative 
scoring system, the Geneva score, involved seven variables and required gas 
exchange and radiographic information. Recently, a revised Geneva score 
requiring eight clinical variables without gas exchange or radiographic 
information was validated and published.  
  
22 
Although such scoring systems have not proven to be more accurate 
than implicit assessment, they do provide a means of standardization that 
compensates for variability in physician experience and judgment. 
 
DIFFERENTIAL DIAGNOSIS 
PE may mimic a large spectrum of diseases. The most common 
differential diagnoses are chronic lung disease, asthma, congestive heart 
failure, pneumonia, acute myocardial infarction, aortic dissection, primary 
pulmonary hypertension, chronic thromboembolic hypertension, pericarditis, 
cancer, pneumothorax, costochondritis, musculoskeletal pain, and anxiety 
states. 
NONIMAGING STUDIES FOR PULMONARY EMBOLISM 
D-Dimer 
The plasma D-dimer is a specific derivative of cross-linked fibrin. 
Measurement of circulating plasma D-dimer has been comprehensively 
evaluated as a diagnostic test for acute VTE. A normal enzyme-linked 
immunosorbent assay (ELISA) is highly sensitive in excluding PE and DVT.  
An increased D-dimer level is nonspecific for PE and may be seen with 
advancing age and in patients with various diseases, including infections and 
other inflammatory states, cancer, myocardial infarction, the postoperative 
state, and second- and third-trimester pregnancies. 
  
23 
 
ARTERIAL BLOOD GAS ANALYSIS 
An important tenet should be that unexplained hypoxemia, particularly 
in the setting of risk factors for DVT, suggests the possibility of PE. 
ELECTROCARDIOGRAPHY 
ECG findings in acute PE are generally nonspecific and include T-
wave changes, ST-segment abnormalities, incomplete or complete right 
bundle-branch block, right axis deviation in the extremity leads, and 
clockwise rotation of the QRS vector in the precordial leads. The changes that 
do occur are likely caused by right-heart dilatation.  
Approximately 20 percent of patients with PE have no 
electrocardiographic changes.  
 The "classic" S1 Q3 T3 pattern described by McGinn and White in 
1935 in seven patients with acute cor pulmonale secondary to PE was 
subsequently demonstrated to be present in approximately 10 percent of PE 
cases.21,22 
 In patients without underlying cardiac or pulmonary disease from the 
Urokinase Pulmonary Embolism Trial (UPET), ECG abnormalities were 
documented in 87 percent of patients with proven PE.  In this clinical trial, 26 
percent of patients with massive or submassive PE and 32 percent of those 
with massive PE23 had manifestations of acute cor pulmonale, such as the S1 
Q3 T3 pattern, right bundle-branch block, a P-wave pulmonale, or right axis 
deviation. The low frequency of specific ECG changes associated with PE 
was confirmed in the PIOPED study. 
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Despite its lack of diagnostic accuracy, ECG may be helpful in 
predicting adverse clinical outcomes in patients with PE. It was recently 
suggested that a T-wave inversion in V2 or V3 is the most frequent ECG sign 
of massive PE. In another PE study, both the pseudoinfarction pattern (Qr in 
V1) and T-wave inversion in V2 were closely related to the presence of right 
ventricular dysfunction and were independent predictors of adverse clinical 
outcome.24  
IMAGING STUDIES FOR PULMONARY EMBOLISM 
Chest Radiography 
The chest radiograph is abnormal in the majority of patients with PE, 
but the findings are nonspecific and often subtle. Atelectasis, cardiomegaly, 
pulmonary infiltrates, small pleural effusions, and mild elevation of a 
hemidiaphragm may be present. 
 Classic radiographic evidence of pulmonary infarction (Hampton 
hump) or decreased vascularity (Westermark sign) are suggestive but 
uncommon. A normal chest radiograph in the presence of significant dyspnea 
and hypoxemia without evidence of bronchospasm or anatomic cardiac shunt 
is strongly suggestive of PE.  
COMPUTED TOMOGRAPHY OF THE CHEST 
Contrast-enhanced computed tomography (CT) of the chest has become 
the most useful imaging test in patients with clinically suspected acute PE. 
 
  
25
First-generation scanners have poor resolution in the segmental 
pulmonary arteries and a limited sensitivity for subsegmental clots. However, 
they appear to predict a benign clinical course over the ensuing 3 months.25, 
Second-generation scanners involve continuous movement of the 
patient through the scanner with concurrent scanning by a constantly rotating 
gantry and detector system. A helix of projecting data is obtained. Continuous 
volume acquisitions can be obtained during a single breath. Rapid scans can 
be obtained, facilitating imaging in critically ill patients. 
The latest generation of multidetector-row CT scanners  permits image 
acquisition of the entire chest with 1-mm or submillimeter resolution with a 
breathhold of less than 10 seconds.26,27 The latest generation of 64-slice scanners 
can image thrombus in sixth-order vessels. 
An additional advantage is evaluating a patient for the entire spectrum 
of VTE in one imaging session by scanning the legs and pelvis, as well as the 
lungs. 
Outcome studies have demonstrated that embolism can be safely 
excluded using a clinical assessment tool, D-dimer testing, and computed 
tomography except in those patients who present with a high clinical 
likelihood of embolism.  
VENTILATION–PERFUSION SCANNING 
V/Q scanning has been the pivotal diagnostic test for suspected PE for 
many years. Chest CT has now virtually replaced lung scanning. 
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PULMONARY ANGIOGRAPHY 
Standard contrast pulmonary arteriography is the established "gold 
standard" imaging test for the diagnosis of PE.  
Prior to injecting contrast agents into the pulmonary artery, optimal 
recording of right-heart pressure tracings is important. If pressure curves 
"wedge" in the main pulmonary arteries, massive PE should be suspected. If 
the mean pulmonary artery pressure exceeds 40 mmHg, preexisting 
pulmonary hypertensive disorders, including chronic thromboembolic 
pulmonary hypertension, should be included in the differential diagnosis.  
The primary sign for PE is an intraluminal filling defect in an arterial 
branch or cutoff of a branch with the visualized tail of the embolus Secondary 
signs of PE are decreased abrupt occlusion of a vessel, oligemia or 
avascularity, prolonged arterial phase with slow filling and emptying of veins, 
and tortuous peripheral vessels.  
In chronic pulmonary hypertension, the pulmonary arteries are pouched 
and contain organized thrombi with usually concave edges. Bands and webs 
within the arteries may be present. Lobar and segmental vessels may show 
abrupt narrowing or occlusion. 
MAGNETIC RESONANCE IMAGING 
Gadolinium-enhanced magnetic resonance (MR) angiography is also 
being used to evaluate clinically suspected PE.28,29 
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A more recent study showed that when MR is performed under optimal 
conditions, it appears to be highly sensitive and specific even for segmental 
PE in comparison to pulmonary angiography.  
ECHOCARDIOGRAPHY 
Transthoracic echocardiography has emerged as a potentially important 
tool for risk assessment and treatment guidance in patients with acute PE. The 
presence of right ventricular dysfunction on a baseline echocardiogram in 
normotensive patients appears to represent an independent predictor of an 
adverse outcome or early death.  
However, approximately 40 percent of normotensive patients with 
symptomatic pulmonary embolism will have echocardiographic evidence of 
right ventricular dysfunction and it remains controversial whether all such 
patients, the majority of whom will do well with conventional therapy, should 
be subjected to the risks of thrombolytic therapy. 
Right ventricular systolic dysfunction in routine clinical practice is 
semiquantitatively assessed by examination of the right ventricular free wall 
motion using a four-point scale normal/near-normal right ventricular function 
and mild, moderate, or severe right ventricular dysfunction. Patients with 
severe right ventricular dysfunction may show regional wall motion 
abnormalities of the right ventricle known as the McConnell sign- evidence of 
severe hypokinesis of the right ventricular free wall combined with preserved 
systolic contraction of the right ventricular apex.30 
 
  
28
 Right ventricular dilatation is an indirect sign of right ventricular 
pressure overload in the setting of acute PE. The ratio of right ventricular to 
left ventricular size should be measured using M-mode echocardiography in 
the parasternal long-axis view at the level between the mitral valve and the 
papillary muscle. An alternative is to measure the size ratio of both ventricles 
in the apical four-chamber view at the level of the atrioventricular valves. A 
ratio of right ventricular to left ventricular size of 1 in the apical four-
chamber view and 0.5 in the parasternal long-axis view indicates right 
ventricular dilation. In patients with severe right ventricular pressure 
overload, a constant shift of the interventricular septum toward the left 
ventricle or a paradoxical (systolic) septal movement toward the left ventricle 
may be observed. In the parasternal short-axis view, a constant shift of the 
septum to the left side often causes a "D-shaped" left ventricle  
Further indirect signs of right ventricular dysfunction are systolic 
pulmonary artery hypertension manifested by an increased tricuspid 
regurgitant velocity >2.6 m/s and reduced inspiratory collapse of a dilated 
inferior vena cava because of elevated central venous pressure. 
DIAGNOSTIC STRATEGY 
The overall diagnostic approach depends on the hemodynamic 
presentation of the patient.  
While rapid diagnosis and therapeutic intervention is required in 
patients with shock and suspected massive PE, there is sufficient time to 
obtain imaging tests in hemodynamically stable patients with suspected PE. 
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PATIENTS WITH SUSPECTED PULMONARY EMBOLISM 
AND SHOCK 
In patients with hypotension or cardiogenic shock associated with 
suspected massive PE, rapid initiation of therapy is potentially lifesaving. The 
definition of massive pulmonary embolism should be based on hemodynamic 
considerations rather than purely anatomic considerations. Irrespective of the 
degree of vascular obstruction, patients with pulmonary embolism who 
present with shock have a mortality rate that approaches 30 percent, whereas 
those suffering a cardiopulmonary arrest have a mortality rate that 
approximates 70 percent.  
Time-consuming imaging tests often can be avoided when emergency 
bedside echocardiography is available. In patients with suspected massive PE 
and evidence of severe acute right ventricular dysfunction on the 
echocardiogram, thrombolysis or embolectomy may be rapidly initiated. A 
caveat to this general recommendation exists in patients presenting with 
decompensated right-heart failure caused by nonembolic forms of pulmonary 
hypertension. 
 Clues to the chronic nature of the right ventricular dysfunction would 
be a history of chronic rather than acute dyspnea, the presence of right 
ventricular hypertrophy rather than simple dilatation, or estimated pulmonary 
artery systolic pressures by echocardiogram greater than approximately 70 
mmHg. 
  
30 
 
PATIENTS WITH SUSPECTED PULMONARY EMBOLISM 
WITHOUT SHOCK 
Pulmonary embolism cannot be excluded without objective testing. The 
history, physical examination, and diagnostic studies, such as a chest 
radiograph, electrocardiogram, or arterial blood gas analysis, can raise or 
lower the clinical suspicion of embolism but are incapable of excluding or 
confirming it unless a clearly identifiable condition (e.g., strategies have been 
investigated and algorithms constructed capable of confirming or excluding 
the diagnosis of embolism under most circumstances. 
In all emergency room or other outpatients, the clinical pretest 
probability for PE should be calculated by implicit assessment or, preferably, 
through a standardized technique. 
A highly sensitive plasma D-dimer assay such as an ELISA should be 
obtained. Unless the pretest probability is high, pulmonary embolism can be 
excluded by a D-dimer result below the assay-specific cutoff level. In patients 
with elevated D-dimer levels or a high clinical probability of embolism, spiral 
chest CT should be obtained. In patients with significant impairment of renal 
function, pregnancy, or allergy to contrast agents, lower-extremity duplex 
study, or ventilation–perfusion scanning may be preferred as the primary 
chest imaging test. 
 Diagnostic strategy for patients with suspected pulmonary 
embolism (PE) without shock. 
In this strategy, chest computed tomography is used as the principal 
imaging test 
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Further testing should be considered if the test is inconclusive or 
negative, with a persistent suspicion of PE.  
The approach to a hospitalized patient with suspected embolism is 
different. At the present time, the safe exclusion of embolism in inpatients 
using a clinical prediction rule and D-dimer result remains to be established. 
D-Dimer testing has little clinical utility in inpatients because of its poor 
specificity.  
At the present time, embolism can be safely excluded in patients with a 
low or intermediate probability of embolism by a normal, highly-sensitive D-
dimer assay, a normal or near-normal ventilation–perfusion scan, a negative 
CT angiogram, or a negative contrast angiogram. In patients with a high 
probability of embolism, clinical outcome appears to be acceptable following 
a negative CT angiogram and lower-extremity duplex examination, but 
definitive exclusion requires either a normal ventilation–perfusion scan or a 
negative contrast pulmonary angiography. Under this circumstance, clinical 
judgment must come into play with the risk of possible recurrence balanced 
against the risk of additional diagnostic procedures.  
Embolism can be confirmed in patients with an intermediate or high 
probability of embolism by a high probability ventilation–perfusion scan, a 
positive CT angiogram, or a positive lower-extremity duplex examination. In 
patients with a low probability of embolism, pulmonary angiography is 
required unless a CT angiogram is positive. 
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MANAGEMENT  
Risk Stratification 
Transthoracic echocardiography is the most important tool for risk 
stratification because right ventricular dysfunction on the echocardiogram is a 
powerful and independent predictor of mortality. From a prognostic point of 
view, echocardiography helps to classify PE into three groups: 
 (1) Low-risk PE (no right ventricular dysfunction) with a hospital 
mortality of <4 percent,  
(2) Submassive PE (right ventricular dysfunction and a preserved 
systemic arterial pressure) with a hospital mortality of 5 to 10 percent, and 
(3) Massive PE (right ventricular dysfunction and cardiogenic shock) 
with a hospital mortality of approximately 30 percent 
CARDIAC BIOMARKERS 
Troponins and natriuretic peptides are similarly accurate in identifying 
low-risk PE  patients.31,32 The negative predictive value for inhospital death is 
high for the biomarker assays The cutoff levels for troponins are the lower 
detection limits for myocardial ischemia reported by the manufacturer. In one 
clinical trial, the cutoff level for the brain natriuretic peptide triage assay to 
predict a benign clinical outcome in PE patients was lower (<50 pg/mL) than 
the "congestive heart failure" cutoff level of 90 pg/mL.33  
 Cumulative survival rate at 30 days in patients with acute pulmonary 
embolism according to the level of troponin T. A level >0.1 ng/mL identifies 
patients at high risk for adverse clinical outcome.  
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 ANTICOAGULATION 
Standard Unfractionated Heparin Unfractionated heparin (UFH) is a 
highly sulfated glycosaminoglycan . Heparin acts primarily by binding to 
antithrombin III (AT III), a protein that inhibits the coagulation factors 
thrombin (factor IIa), Xa, IXa, XIa, and XIIa.accelerates its activity 
approximately 100- to 1000-fold. 
 This prevents additional thrombus formation and permits endogenous 
fibrinolytic mechanisms to lyse clot that has already formed. 
 Heparin does not directly dissolve thrombus that already exists.  
Heparin is the cornerstone of treatment for acute PE. Before starting 
heparin, evaluate potential risk factors for bleeding, such as a prior history of 
bleeding with anticoagulation, thrombocytopenia, vitamin K deficiency, 
increasing age, underlying  diseases, and concomitant drug therapy 
When intravenous unfractionated heparin is instituted, the activated 
partial thromboplastin time (aPTT) should be aggressively followed at 6-hour 
intervals until it is consistently in the therapeutic range of 1.5 to 2.0 times 
control values.  Heparin can be administered as an intravenous bolus of 5000 
U followed by a maintenance dose of at least 30,000 U every 24 hours by 
continuous infusion.34 An alternative regimen consisting of a bolus of 80 
U/kg followed by 18 U/kg/h has been recommended.35,36 Subsequent dose 
modifications, based on aPTT as follows:  
a. APTT  Heparin Dose Adjustment   
b. Seconds  Times Control   
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c. <35 <1.2 80 U/kg bolus, then increase by 4 U/kg/h  
d. 35 to 45 1.2 to 1.5 40 U/kg bolus, then increase by 2 U/kg/h  
e. 46 to 70 1.5 to 2.3 No change  
f. 71 to 90 2.3 to 3 Decrease infusion rate by 2 U/kg/h  
g. >90 >3 Hold infusion 1 h, then decrease rate by 3 U/kg/h  
UPPER-EXTREMITY DVT 
 Effort-related upper-extremity venous thrombosis (Paget-Schroetter 
syndrome) affects young, active men and is related to extrinsic compression 
of the subclavian vein at the thoracic inlet. A multidisciplinary approach to 
management is often required to avoid long-term consequences including 
recurrence, embolism, and symptomatic sequelae.37 
Potential Advantages of Low-Molecular-Weight Heparins over 
Unfractionated Heparin  
1) Efficacy: comparable or superiora 
2) Safety: comparable or superiorb 
3) Bioavailability: superior  
4) Subcutaneous administration  
5) Once- or twice-daily dosing  
6) No laboratory monitoring 
7) Less phlebotomy  
8) Earlier ambulation 
9) Home therapy in certain patient subsets  
LMWH   
Enoxaparin 30 mg q12h or 40 mg qd 1 mg/kg bid, 1.5 mg/kg qda 
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Dalteparin 2500 to 5000 Xa U qd 200 Xa U/kg qd  
Enoxaparin is the only LMWH approved for use in the United States It 
is indicated in patients who present with DVT (with or without concomitant 
pulmonary embolism [PE]). A dose of either 1.5 mg/kg or 1 mg/kg q12h has 
proven effective for inpatients with DVT ± PE.  
Optimal Duration and Intensity of Anticoagulation 
 Patients with a clearly defined initial predisposition, whose initial 
thromboembolic risk factors have resolved and whose ventilation–perfusion 
scan and noninvasive lower-extremity testing have normalized, can be 
managed with a 3-month course of anticoagulation. 
 Patients without a clearly defined initial predisposition to abnormal 
lower-extremity test results should be treated for 6 months or more.  
Patients, such as those with recurrent spontaneous episodes of venous 
thromboembolism, an irreversible clinical risk factor, combined 
thrombophilic tendencies, antithrombin III deficiency, or the presence of a 
lupus anticoagulant, should be treated with an indefinite period of 
anticoagulation even though such a strategy is associated with an increased 
risk of bleeding complications. 
Vena Cava Interruption 
In patients with established VTE in whom heparin therapy cannot be 
continued, inferior vena cava (IVC) filter placement can be undertaken to 
prevent lower-extremity thrombi from embolizing to the lungs.38  
Greenfield filter design is the most widely used.39  
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THROMBOLYTIC THERAPY 
Systemic Thrombolysis 
The role of thrombolytic therapy in pulmonary embolism should be 
limited to those circumstances in which an accelerated rate of thrombolysis 
with hemodynamic compromise, patients who develop hemodynamic 
compromise during conventional therapy with heparin, and patients with 
embolism associated with intracavitary right-heart thrombi. 
 At the present time, the finding of right ventricular dysfunction on 
echocardiography in the absence of hemodynamic instability should not serve 
as a justification for routine thrombolytic therapy. 
There are only 10 randomized PE trials of thrombolysis versus heparin 
to date, with a total of 717 patients with varying severity of PE. In an 
overview, there is a trend toward mortality reduction with thrombolysis.40-46  
None of the thrombolytic agents have been shown to be superior to the 
others. FDA-approved thrombolytic agents include recombinant tissue 
plasminogen activator, streptokinase, and urokinase. presents thrombolytic 
regimens for the treatment of PE.  
REGIMENS FOR SYSTEMIC THROMBOLYTIC THERAPY 
IN PULMONARY EMBOLISM  
Lytic Agent Dose Regimen  
Streptokinase Loading dose: 250,000 U IV  
Continuous infusion: 100,000 U/h for 24 h  
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Urokinase Loading dose: 2000 U/lb IV over 10 min  
Continuous infusion: 2000 U/lb/h for 12–24 h  
Alteplase (tPA) Loading dose: none  
Continuous infusion: 100 mg over 2 h  
Reteplase 1. Bolus: 10 U IV  
2. Bolus: 10 U IV after 30 min  
tPA, tissue plasminogen activator. 
Heparin should be withheld until the thrombolytic infusion is 
completed. The aPTT is then determined and heparin is initiated without a 
loading dose if this value is less than twice the upper limit of normal. If the 
aPTT exceeds this value, the test is repeated every4 hours until it is safe to 
proceed with heparin. 
 It is reasonable to consider systemic thrombolytic therapy in patients 
with proximal occlusive DVT associated with significant swelling and 
symptoms when there are no contraindications. 
CATHETER FRAGMENTATION AND EMBOLECTOMY 
Interventional thrombus fragmentation with or without embolectomy is 
an alternative to systemic thrombolysis or surgical embolectomy. If the 
bleeding risk is not exceedingly high, catheter fragmentation may be 
combined with local or systemic thrombolysis.  
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 SURGICAL EMBOLECTOMY 
Acute embolectomy might be considered in patients with 
hemodynamically massive pulmonary embolism or right-heart thrombus who 
have an absolute contraindication to anticoagulant or thrombolytic therapy, in 
patients who have suffered a cardiopulmonary arrest (although the mortality 
associated with embolectomy in those who have experience arrest is far 
higher than those who have not), in patients with impending paradoxical 
embolism, and in patients in whom aggressive medical therapy, including the 
use of thrombolysis, has proven ineffective. 
SUPPORTIVE MEASURES 
When massive PE associated with hypotension and/or severe 
hypoxemia is suspected, supportive treatment is immediately initiated. 
Intravenous saline can be infused rapidly, but caution is recommended. 
Excess fluid can result in further right ventricular dilatation, increased right 
ventricular wall tension, and a decreased cardiac output that may result in 
right ventricular ischemia. Dopamine or norepinephrine appear to be the 
favored choices of vasoactive therapy in massive PE and should be 
administered if the blood pressure is not rapidly restored. Death from massive 
PE results from right ventricular failure, and dobutamine has been 
recommended by some as a means by which to augment right ventricular 
output47,48 might offer optimal results. Mechanical ventilation may be 
instituted to decrease systemic oxygen demands or to manage respiratory 
failure. Intubation in the setting of a decompensated right ventricle, however, 
is fraught with risk. Premedications may cause systemic vasodilatation,  
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whereas positive pressure ventilation may abruptly reduce preload and cardiac 
output. 
CHRONIC THROMBOEMBOLIC PULMONARY 
HYPERTENSION 
In a few patients with acute PE, the residual thromboembolic burden is 
sufficiently extensive to cause thromboembolic pulmonary hypertension. A 
variety of CT abnormalities have been described in patients with chronic 
thromboembolic disease including right-sided cardiac enlargement, 
enlargement of the pulmonary arteries, a mosaic perfusion pattern, 
intraluminal thrombus, subpleural densities, and dilated bronchial arteries.49 
The absence of these findings, however, cannot absolutely exclude the 
diagnosis.  
Following acute embolism, stable hemodynamics are achieved within 6 
to 8 weeks.50 Consequently, to avoid the possible development of a 
secondary, small-vessel arteriopathy that ultimately contributes to the 
elevation in pulmonary vascular resistance and which is not amenable to 
surgical correction, there is no need to delay evaluation beyond 3 months. 
Right-heart catheterization and contrast pulmonary arteriography are 
performed to establish the diagnosis with certainty and to determine 
operability. The angiographic findings in chronic thromboembolic pulmonary 
hypertension are distinct from those encountered in acute embolism and 
considerable experience is required for accurate angiographic interpretation  
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MATERIAL AND METHODS 
This study was performed in the Department of Cardiology, Rajiv 
Gandhi  Government General Hospital, Chennai, during the year 2008 – 2011. 
The study is a prospective observational study involving 50 patients. 
STUDY GROUP SELECTION 
Ethical committee clearance was obtained to conduct the study in our 
hospital.  
All subjects provided written informed consent to participate in the 
study before inclusion.  
50 consecutive patients with symptoms of 
unexplained dyspnoea 
chest pain  
fainting, 
 ECGor ECHO signs of acute corpulmonale  
were taken as cases of suspected PE.  
All the  patients underwent ,physical exam, ECG,ECHO  d-dimer 
assay, CT pulmonary angiogram and other relevant examinations. 
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All the  patients underwent, probability of PE assessment for Pisa, 
Wells, and Revised Geneva Model. They were  categorized into low, 
intermediate , high in each score as per the criteria in each category 
PISAMODEL 
Sex  
Age  
Immobilization  
Deep vein thrombosis  
Cardiovascular Pre-existing 
disease 
 
Pulmonary Pre-existing 
disease 
 
Dyspnoea (Sudden- onset)  
Orthopnea  
Chest pain  
Fainting(syncope)  
Hemoptysis  
Leg Swelling(Unilateral)  
Fever>380 C (>100.40F)  
Wheezes  
Crackles  
Acute Corpulmonale in 
ECG 
 
 
PROBABILITY OF PE IN PISA MODEL 
LOW:                                0-10% 
INTERMEDIATE:          11-50% 
HIGH >50% 
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WELLS SCORE 
PREDISPOSING FACTORS POINTS 
PREVIOUS DVT OR PE  +1.5 
RECENT SURGERY OR 
IMMOBILISATION  
+1.5 
CANCER  +1 
SYMPTOMS   
HEMOPTYSIS  +1 
CLINICAL SIGNS   
HEART RATE>100/MIN  +1.5 
CLINICAL SIGN OF DVT  +3 
CLINICAL JUDGEMENT   
ALTERNATE DIAGNOSIS LESS 
LIKELY THAN PE  
+3 
 
CLINICAL  
PROBABILTY (3 –LEVEL) 
WELLS 
TOTAL 
LOW  0 TO 1 
INTERMEDIATE  2 TO 6 
HIGH  ≥ 7 
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REVISED GENEVA SCORE 
PREDISPOSING FACTORS POINTS
AGE>65 YRS  +1 
PREVIOUS DVT OR PE  +3 
SURGERY OR FRACTURE IN 1 MONTH  +2 
ACTIVE MALIGNANCY  +2 
SYMPTOMS  
UNILATERAL LOWER LIMB PAIN  +3 
HEMOPTYSIS  +2 
CLINICAL SIGNS  
HEART RATE   
75 TO 94 /MIN  +3 
≥94 /MIN  +5 
PAIN ON LOWER LIMB DEEP VEIN PALPATION AND 
UNILATERAL EDEMA  
+4 
 
CLINICAL PROBABILITY TOTAL
LOW  0 TO 3 
INTERMEDIATE  4 TO 10
HIGH  ≥11 
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In each patient, probability of pulmonary embolism is calculated 
for all the three models-pisa  wells and revised geneva score  
IN ECG 
Following findings were looked in patients  for acute corpulmonale 
1 T wave inversion v1 – v4 
2 Tachycardia 
3 S1Q3T3 pattern 
4 RBBB 
5 Rightaxisdeviation  
ECG 
 
ECG from one of the study patient showing classical finding of PE 
1. S1Q3T3 
2. Tachycardia 
3. RV Strain 
4. incomplete RBBB 
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          VENTILATION-PERFUSION  SCAN  
                
 
Ventilation –perfusion scan from one of our study  patient  showing mis-match 
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ECHOCARDIOGRAPHY  
Echocardiography was done immediately in all the patients by Philips 
Envisor  which produces good imaging quality 
Following specific  findings were looked in the ECHO 
 RA RV dilatation.  
A constant shift of the interventricular septum toward the left ventricle 
or a paradoxical (systolic) septal movement toward the left ventricle 
"D-shaped" left ventricle  
Increased tricuspid regurgitant velocity >2.6 m/s  
Reduced inspiratory collapse of a dilated inferior vena cava 
 McConnell sign: evidence of severe hypokinesis of the right 
ventricular free wall combined with preserved systolic contraction of the right 
ventricular apex  
Shortened PA acceleration time less than 60-100 ms particularly in the 
presence of RVsystolic pressure less than 60 mm Hg-specific for acute PE  
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D Shaped septum 
 
 
 
 
RA RV Dilatation 
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TR PG 50 mmHg 
 
 
PULMONARY ARTERY PRESSURE –66/23-MEAN 36 
 PULMONARY ARTERY PRESSURE TRACING OF PE  IN ONE OF 
OUR PATIENT 
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64-SLICE CT PULMONARY ANGIOGRAM 
64 Slice CT Pulmonary Angiogram is done for all patients to confirm 
presence or absence of PE as per the current methodology 
 It is done in all the patients before Thrombolysis in our radiology 
department which is adjacent to our department 
 The primary sign for PE is an intraluminal filling defect in an arterial 
branch or cutoff of a branch with the visualized tail of the embolus 
 Secondary signs of PE are decreased abrupt occlusion of a vessel, 
oligemia or avascularity of a segment 
 
Pulmonary Angiogram Showing filling defect and 
poor peripheral vascular blood supply with cut off sign. 
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Dilated pulmonary artery and filling defect. 
 
64-Slice CT Pulmonary Angiogram showing filling defect and poor 
peripheral vascular blood supply with cut off sign. 
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RESULTS 
 Patient Characteristics 
           Total number of patients 50 
           In the age group15-56 35 patients, 57-67 14 patients, 68-74 1patient 
 
 In the study group 38 patients were males and 12 patients were 
females 
20 patients were proven to have pulmonary embolism.  
The most common symptom was sudden onset dyspnoea in 15 patients 
History of immobilization found in 8 patients. 
DVT was found in 9 patients 
RV strain in ECG was found in 10 patients 
S1Q3 pattern in ECG was found in 11 patients 
ECHO showed RV enlargement in 12 patients 
TR PG greater than 40 mm Hg was found in 14 patients 
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                 PATIENT CHARACTERISTICS 
 
PATIENT 
CHARACTERISTICS NO. OF PATIENTS 
PERCENTAGE 
(%) 
Age 
15-56 
57-67 
68-74 
75-94 
 
35 
14 
1 
0 
 
70% 
28% 
2% 
0% 
Gender 
Male 
Female 
 
38 
12 
 
76% 
24% 
DVT 9 45% 
RV strain in ECG 10 50% 
S1Q3 pattern 11 55% 
RV enlargement  12 60% 
TR PG 14 70% 
Pulmonary Embolism 20 40% 
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In the study group 38 patients were males and 12 patients were 
females. 
SEX DISTRIBUTION
Male Female
 
 
20 patients were proven to have pulmonary embolism 
INCIDENCE OF PE IN THE STUDY
Pulmonary Embolism Pulmonary Embolism-Absent
. 
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Among 50 patients Pisa Model has predicted low probability in 36%, 
intermediate probability in another 36% and high probability in 28% 
Among 50 patients Wells Model has predicted low probability in 30%, 
intermediate  probability in another 52% and high  probability in 18%  
Among 50 patients Geneva Model has predicted low probability in 18% 
, intermediate probability in another 50% and high  probability in 32%. 
PERCENTAGE OF PROBABILITY OF PE 
 
MODEL 
LOW 
PROBABILITY  
(%) 
INTERMEDIATE 
PROBABILITY 
(%) 
HIGH 
PROBABILITY  
(%) 
PISA MODEL  36 36 28 
WELL SCORE  30 52 18 
REVISED GENEVA 
SCORE  
18 50 32 
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INCIDENCE OF PULMONARY EMBOLISM 
MODEL 
LOW 
PROBABILITY 
(%) 
INTERMEDIATE 
PROBABILITY (%)
HIGH 
PROBABILITY  
(%) 
 PISA  6 37 97 
WELLS  
SCORE  
11 50 66 
REVISED 
GENEVA 
MODEL  
55 40 44 
In Pisa Model when the probability is low there was 1 case of PE, 
when it is intermediate there were 6 cases and when the probability is high 
there were  13 cases 
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In Wells Model when the probability is low there were 2 cases of PE, 
when it is intermediate there were 13 cases and when the probability is high 
there were  5 cases 
 
In Revised Geneva Model when the probability is low there were 5 
cases of PE, when it is intermediate there were 10 cases and when the 
probability is high there were  5 cases 
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Comparison of incidence of pulmonary embolism after calculating 
probability from WELLS SCORE PISAMODEL AND REVISED 
GENEVA SCORE was done with chi square test. 
                        PISA MODEL 
 PE Low Intermediate High Pearson chi square test 
Pisa 
model 
no 17(94.4%) 12(66.7%) 1(7.2%) χ2=25.51 
P=0.001*** yes 1(5.6%) 6(33.3%) 13(92.8%)
** highly significant   *** very high significant 
In the above tabular column Pisa Model is shown to be very highly 
significant in all low, intermediate and high in calculating the probability of 
pulmonary embolism.  
When the probability is high the incidence of pulmonary embolism is 
nearly above 92% 
When the probability is low incidence is less than 6% 
Thus the Pisa Model has very good sensitivity and specificity in 
predicting the probability of presence of PE when the score is high 
When the score is low Pisa Model  has good sensitivity and specificity 
in predicting the absence of PE 
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                  WELLS MODEL 
 PE Low Intermediate High Pearson chi square test 
Well 
score 
no 13(86.7%) 13(50.0%) 4 
(45%) χ2=7.99 
P=0.01** yes 2(14.3%) 13(50.0%) 5 
(55%) 
** highly significant   *** very high significant 
In the above tabular column Wells model is shown to be significant in 
all low, intermediate and high in calculating the probability of pulmonary 
embolism. 
 When the probability is high the incidence of pulmonary embolism is 
nearly 55% only when compared to Pisa Model which has incidence of 92% 
When the probability is low incidence is 14% when compared to Pisa 
Model which has incidence of 5.6% 
Thus the Pisa Model has very good sensitivity and specificity in 
predicting the probability of presence of PE when the score is high than 
Wells Model 
When the score is low Pisa Model  has good sensitivity and specificity 
in predicting the absence of PE than Wells Model 
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REVISED GENEVA SCORE 
 PE Low Intermediate High Pearson chi square test 
Geneva 
No 4(44.4%) 15(60.0%) 11(68.8%) χ2=1.41 
P=0.49 yes 5(55.6%) 10(40.0%) 5(31.2%) 
** highly significant   *** very high significant 
GENEVA model did not show any significance and this model is found 
to be not useful.  
In each low intermediate high all the three scores were assessed for 
significance and found to be significant.  
 
Low Pisa model Well score RGS Pearson chi square test 
Yes 1(5.6%) 2(14.3%) 5(55.6%) χ2=10.22 
P=0.001*** No 17(94.4%) 13(86.7%) 4(44.4%) 
 
Intermediate Pisa model 
Well 
score RGS 
Pearson chi square 
test 
Yes 13(92.8%) 6(66.7%) 5(31.2%) χ2=12.10 
P=0.001*** No 1(7.2%) 3(33.3%) 11(68.8%)
 
High Pisa model Well score RGS 
Pearson chi square 
test 
Yes 6(33.3%) 13(86.7%) 10(40.0%) χ2=11.06 
P=0.001*** No 12(66.7%) 2(14.3%) 15(60.0%) 
** highly significant   *** very high significant 
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DISCUSSION  
 Pisa model is entirely based on the evaluation of relevant clinical 
symptoms and signs, and the interpretation of the electrocardiogram. 
Therefore, it is applicable in any clinical context 
 Among the symptoms, sudden-onset dyspnea is a strong predictor of 
pulmonary embolism. The importance of characterizing dyspnea in terms of 
onset has long been recognized but it was largely overlooked in most studies 
reported thus far  Although the interpretation of the electrocardiogram 
requires medical expertise, the abnormalities associated with acute cor 
pulmonale are based on clearly defined criteria, which have been known and 
applied for many years  
In terms of predictive accuracy, model outperformed those reported by 
others  
Among the patients with pulmonary embolism, there was a strong 
relation between the clinical probability predicted by the model and higher the 
probability, the greater the incidence of PE.  
The present model include variables that are negatively associated with 
pulmonary embolism. This gives the models greater flexibility, which may 
explain why they perform equally well in detecting and in ruling out 
pulmonary embolism.  
Also, instead of using a point-scale score proportional to the regression 
coefficients, typical of other approaches we estimate the probability of 
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pulmonary embolism directly from the sum of the regression coefficients. 
This allows predicting the clinical probability as a continuous function and 
precise estimation of likelihood ratios. 
 The relative complexity of the calculation can be overcome by using 
dedicated software that permits online computation of clinical probability. 
Software is available.  It can be uploaded via the Internet on desktop, laptop, 
and palm computers, and mobile phones.  
The clinical probability predicted by the model can be used by 
physicians as the pretest probability in calculating the posttest probability of 
pulmonary embolism appropriate  
The model which is found to be very useful in Italy is also very useful 
in India. 
In Italy Model the frequencies of PE were 50% in  low probability  
Geneva  model,12% in low  probability wells model and 5% in low 
probability Pisa Model  
In our study the frequencies of PE were 55.6% in low probability 
Geneva model, 14% in low probability wells model and 5% in low probability 
Pisa Model.  
In Italian Model the frequencies of PE were 39% in intermediate 
probability Geneva  model,54 % in intermediate  probability wells model and 
42% in intermediate probability Pisa Model. 
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 In our study the frequencies of PE were 40% in intermediate 
probability Geneva model,50 % in intermediate  probability wells model and 
33% in intermediate probability Pisa Model  
In Italy Model the frequencies of PE were 49% in high probability 
Geneva model, 64 % in high probability wells model and 98% in high 
probability Pisa Model. 
In Our Study Italy Model the frequencies of PE were 44% in high 
probability Geneva model, 66 % in high  probability wells model and 97% in 
high probability Pisa Model  
Our Indian study more or less follows the same results as Pisa study –
Italian Model  
Pisa Model is found to be better than Wells and Revised Geneva 
model in predicting the presence or absence of pulmonary embolism 
Le Gal G, et al in a study of Prediction of pulmonary embolism in the 
emergency department for the revised Geneva score have found the 
prevalence of pulmonary embolism was 8% in the low-probability category (0 
to 3 points), 28% in the intermediate-probability category (4 to 10 points), 
and 74% in the high-probability category (> or =11 points) 
Stewart et al., in a study of the prevalence of pulmonary embolism  
have found 15% in the low-probability category, 29% in the intermediate-
probability category, and 59% in the high-probability category 
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Calisir C, et al., in a study of Performance of the Wells and Revised 
Geneva scores for predicting pulmonary embolism have found the rates of PE 
in high, moderate, and low PE risk groups determined according to the Wells 
score and were 89.6, 26.4, 7.8 and the Revised Geneva score 83.3, 25.6, 0%, 
respectively.  
Yap KS, et al., in a study of prospective reassessment of the utility of 
the Wells score in identifying pulmonary embolism have noted the likelihood 
of PE for a given Wells score in study was not significantly different from the 
likelihood in the original study by Wells et al. Scores of < 2 in our study were 
associated with a 4% risk of PE, scores between 2 and 6 with a 13% risk, and 
scores > 6 with a 67% risk.  
Reshma Khetpal, MD et al., in a study of Predictability of Wells Score 
for the Diagnosis of Acute Pulmonary Embolism have found,  among patients 
with positive-CTA:0%had- low probability ,62.5%had- intermediate 
probability and 37.5% had-high probability .Among the negative-
CTA:85%had-lowprobability 15% had intermediate probability and 0% had-
high probability Using high probability and intermediate probability as 
positve probability and low probability as negative probability for PE, the 
sensitivity, specificity,negative predictive value and positive predictive value 
were 100%,85%,100%, and 34.8%respectively 
Compared with above studies Pisa Model found  to be  better than 
Wells and Revised Geneva Model 
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During the study we noted following  
 
1  History of immobilisation is important 
2  When ECG shows S1Q3T3or RV strain pattern one has to suspect PE       
 in appropriate clinical setting 
3      When ECHOshows RVdilataion with TR Pg 40-70mmhg with sudden  
 onset  dyspnoea, suspiscion is high 
4         ECHO  is ambiguous in finding thrombus in pulmonary artery because 
 of artifact 
In Emergency quick assesment of probability of  PE is important  because missing or 
not suspecting maybe fatal 
USEFULNESS OF ASSESSING THE PROBABILITY 
 
 
 
 
 
ASSESS PROBABILITY 
High 
64 Slice CTA 
Low/ Intermediate 
D Dimer 
Negative 
No further 
evaluation 
Positive 
64 Slice CT 
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CONCLUSIONS 
The diagnosis of Pulmonary Embolism primarily involves continuous 
vigil and probability assessment in vulnerable population.Various risk 
prediction models are available  
 
1. In this study where all the three models were compared, the Italian Pisa 
Model is simple, easy and more accurate than other models (wells 
score and Revised Geneva Score) when assessing the clinical 
probability of pulmonary embolism in Indian population   
 
 
2. Predictive value of Pisa model can be further improved, if 
echocardiographic parameters are also incorporated in the criteria.  
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LIMITATIONS OF THE STUDY 
 
1. The number of patients included in this study is less. 
2. Our study population was highly selective 
3.  Smaller PEs may have been missed. 
4. Some patients might have died before arrival to the hospital 
5. IMCU patients could not be fully evaluated 
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 GLOSSARY & ACRONYMS  
PE - Pulmonary embolism  
CAD  -  Coronary artery disease 
CT - Computed Tomography 
LMWH  -   Low Molecular Weight Heparin 
LV  –  Left ventricle 
TTE - Trans Thoracic Echocardiogram. 
MRI  -  Magnetic Resonance Imaging. 
RV                      -    Right  Ventricle  
EDD  – End Diastolic Diameter 
EF  –  Ejection Fraction 
ECG  -  Electrocardiography 
DVT –   Deep Venous Thrombosis 
RA                       -   Right Atrium 
 RBBB-               - Right Bundle  Branch Block  
ELISA-                  -   Enzyme Linked Immunosorbent Assay 
SHT                      -   Systemic Hyper Tension 
DM                       -   Diabetes Mellitus 
PIOPED                 - Prospective Investigation Of Pulmonary Embolism 
 PROFORMA 
Serial no:                                Initials:                                 Contact no: 
Age :                                       sex:            Address: 
CD no: 
Diagnosis: 
SHT:             DM:      
History of.Prolonged immobilisation  
History of DVT 
History of PE 
History of surgery or fracture in 1 month 
History of active malignancy 
Unilateral limb pain 
Heart rate 
Pain on lower limb deep vein palpation                
Sudden onset dyspnea  
Chest pain 
Syncope 
Hemoptysis 
Unilateral leg swelling 
 Ecg signs of acute cor pulmonale 
1  T wave inversion v1 – v4 
2 Tachycardia 
3 S1Q3T3 pattern 
4 RBBB 
5 Rightaxisdeviation  
 Prior cardiovascular disease 
Prior respiratory disease 
Orthopnea 
High fever 
Wheeze 
Crackles  
Blood pressure:                                   Pulse: 
CVS:                                                   RS: 
Investigations 
D-Dimer 
Blood sugar; 
Serum creatinine: 
Haemoglobin:  
Complete Blood Count: 
Chest X-Ray -PA view: 
ECG: 
ECHO parameters: 2 D, M Mode and Doppler study: 
LVIDD;                 LVISD; 
EF; 
TR peak velocity; 
Mcconnells sign; 
Pulmonary artery thrombus; 
RV dilatation; 
RV function;    
TDI tricuspid annulus; 
PA acceleration time;          
CT PULMONARY ANGIOGRAM    
Thrombus 
  
